Sees FY25 net product sales $185M-$192M; and contract revenues from collaborations $15M-$18M. The company added, “The revenue ranges above exclude approximately $40.0 million in non-cash revenue that Rigel expects to recognize in the Q2 related to the release of the remaining cost share liability from Rigel’s collaboration with Lilly for the development and commercialization of ocadusertib. The company anticipates it will report positive net income for the full year 2025, while funding existing and new clinical development programs.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue